Our findings indicate that the use of currently FDA-approved drugs against proteasomal degradation and/or tailor-made therapies mimicking the TGFβ/Smad3/MEN1 signaling pathway would be highly beneficial for melanoma patients, as these drugs would efficiently prevent initial tumor formation/progression and further hinder the spread of metastatic tumors to secondary organs. Here, SMAD3 is linked to neoplasm.